RxDoctor Payments Data

Garrett Galt

Nurse Practitioner · Cedar City, UTNPI 1578207999

Payments from drug & device makers

$810in general payments, 2019–2025

Across 51 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$196
  • Novo Nordisk$97
  • Xeris Pharmaceuticals, Inc.$69
  • Sanofi-aventis U.S. LLC$57
  • Novartis$53
  • Bayer$48
  • plus $289 from 12 others

What the payments were for

  • Food & beverage$810100%
  • Education$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 75th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$29,646
Medicare patients
138
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide267$339,221
RybelsusSemaglutide81$99,939
JardianceEmpagliflozin81$93,368
TrulicityDulaglutide26$38,739
OzempicSemaglutide35$36,858
Tresiba Flextouch U-100Insulin Degludec48$25,844
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$24,937
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$24,028
Lantus SolostarInsulin Glargine,hum.Rec.Anlog169$22,899
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$20,990
MyrbetriqMirabegron45$20,254
Lyumjev Kwikpen U-100Insulin Lispro-Aabc19$17,545
Tresiba Flextouch U-200Insulin Degludec20$17,463
Gvoke Hypopen 2-PackGlucagon26$17,428
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$17,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$196$377,961293 claims
Novo NordiskRybelsus, Ozempic, Novolog$97$138,457131 claims
Boehringer IngelheimJardiance$47$93,36881 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog$57$16,41325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Cedar City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →